ArticleCNS neuroscience & therapeutics2026
Clinical Utility of Z-Score Distribution Mapping in Epileptogenic Zone Localizations.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThis study aimed to evaluate the clinical utility of positron emission tomography (PET)-based Z-score distribution mapping (Z-map) in the noninvasive presurgical localization of seizure onset zones (SOZs), with a particular focus on regional differences in performance and methodological robustness.
methodsWe analyzed a cohort of 120 patients with drug-resistant epilepsy who underwent stereoelectroencephalography (SEEG) implantation between 2021 and 2024. Multimodal imaging data, including PET and structural MRI, were processed using FreeSurfer and 3D Slicer to reconstruct electrodes, segment gray matter, and generate Z-maps. Hypometabolic regions were defined as the bottom 0.5% of Z-scores. The classification performance of the Z-map was validated against SEEG-defined SOZs.
resultsThe Z-map showed high classification performance in the frontal and parietal lobes (sensitivity: 0.74/0.72; κ: 0.68/0.65), but reduced effectiveness in the temporal and insular lobes (sensitivity: 0.41/0.65; κ: 0.44/0.47). The overall specificity (0.94) and negative predictive value (0.91) indicated strong exclusionary capability. Regional disparities were primarily attributed to anatomical complexity and technical limitations.
conclusionZ-map offers clinically valuable support for localizing SOZs in the frontal and parietal cortex and optimizing SEEG implantation, particularly in patients with inconclusive noninvasive findings. However, its limited sensitivity in temporal and insular regions and high dependency on preprocessing quality underscore the need for standardized pipelines and multimodal integration. Future research should focus on improving robustness and reproducibility to facilitate clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.